Log in

NASDAQ:REPL - Replimune Group Stock Price, Forecast & News

$17.37
-0.60 (-3.34 %)
(As of 01/26/2020 04:00 PM ET)
Today's Range
$17.08
Now: $17.37
$18.00
50-Day Range
$13.63
MA: $15.95
$19.08
52-Week Range
$10.00
Now: $17.37
$19.66
Volume86,331 shs
Average Volume137,024 shs
Market Capitalization$556.01 million
P/E RatioN/A
Dividend YieldN/A
Beta3.03
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPL
CUSIPN/A
CIKN/A
Phone781-995-2443

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.36 per share

Profitability

Net Income$-30,830,000.00

Miscellaneous

Employees62
Market Cap$556.01 million
Next Earnings Date2/13/2020 (Estimated)
OptionableNot Optionable

Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.


Replimune Group (NASDAQ:REPL) Frequently Asked Questions

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

How were Replimune Group's earnings last quarter?

Replimune Group Inc (NASDAQ:REPL) posted its earnings results on Monday, November, 11th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. View Replimune Group's Earnings History.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Replimune Group.

What price target have analysts set for REPL?

5 brokers have issued 1 year price targets for Replimune Group's stock. Their forecasts range from $12.50 to $30.00. On average, they expect Replimune Group's stock price to reach $24.10 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View Analyst Price Targets for Replimune Group.

What is the consensus analysts' recommendation for Replimune Group?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Replimune Group.

What are Wall Street analysts saying about Replimune Group stock?

Here are some recent quotes from research analysts about Replimune Group stock:
  • 1. According to Zacks Investment Research, "Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. " (1/24/2020)
  • 2. Chardan Capital analysts commented, "We expect the 4Q19 data from the phase I portion, potentially at the Cancer (SITC) annual meeting in November, will focus on safety and early signals of immune activity of RP1 as a single agent and in the combo setting. Per management, the company plans to accumulate data from the phase II cohorts over the next ~6 months and begin reporting on a per cohort basis over 2020 (consistent with prior timelines). RP1 trial, a registration-directed randomized controlled study in cutaneous squamous cell carcinoma (CSCC) +/- Regeneron’s (unrated) anti-PD1 cemiplimab is expected to begin in August. Replimune ended the quarter with $120.8 mm in cash, cash equivalents and short-term investments. This provides the company with a cash runway into calendar year 2H21." (8/15/2019)

Has Replimune Group been receiving favorable news coverage?

Media headlines about REPL stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Replimune Group earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Replimune Group.

Are investors shorting Replimune Group?

Replimune Group saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 543,500 shares, a decline of 22.6% from the December 15th total of 702,300 shares. Based on an average daily volume of 170,600 shares, the short-interest ratio is currently 3.2 days. Approximately 4.5% of the shares of the company are short sold. View Replimune Group's Current Options Chain.

Who are some of Replimune Group's key competitors?

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Fate Therapeutics (FATE), Energy Transfer LP Unit (ET), Myovant Sciences (MYOV), Pfizer (PFE), Amarin (AMRN), Axsome Therapeutics (AXSM), Carnival (CCL), Cleveland-Cliffs (CLF) and CVS Health (CVS).

Who are Replimune Group's key executives?

Replimune Group's management team includes the folowing people:
  • Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)
  • Dr. Robert Coffin, Pres, CEO & Director (Age 54)
  • Dr. Colin Love, Chief Operating Officer (Age 61)
  • Dr. Pamela Esposito, Chief Bus. Officer (Age 45)
  • Stephen Gorgol, Chief Accounting Officer

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $17.37.

How big of a company is Replimune Group?

Replimune Group has a market capitalization of $556.01 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe.View Additional Information About Replimune Group.

What is Replimune Group's official website?

The official website for Replimune Group is http://www.replimune.com/.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-995-2443 or via email at [email protected]


MarketBeat Community Rating for Replimune Group (NASDAQ REPL)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote "Outperform" if you believe REPL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Featured Article: Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel